Henrik N.
- Country
- Denmark
- Department
- Infectious Diseases
Research Overview
- Randomized, Double‑Blind, Placebo‑Controlled Trial of Long‑Acting bNAbs 10‑1074‑LS and 3BNC117‑LS with Low‑Dose Nivolumab for Durable HIV‑1 Remission during ART Interruption
- Evaluation of Abatacept and Placebo in Hospitalized Adults with COVID-19: A Randomized, Controlled Trial on Immune Modulation Strategies
- Phase 3 Evaluation of ExPEC9V Vaccine for Preventing Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60+ with Prior Urinary Tract Infection
Data & Insights
Has run more than one trial at 56 of 216 partner sites.
Specializations
Viral Infections
This investigator demonstrates extensive expertise in treating viral respiratory infections and COVID-19, particularly focusing on innovative therapeutic approaches for hospitalized patients.
- COVID-19 treatment strategies
- Antiviral therapeutics
- Immunoglobulin therapy
The research explores both outpatient and inpatient treatment modalities for viral infections.
Infectious Diseases
The investigator specializes in managing various infectious conditions, including HIV infection and bacterial diseases caused by E. coli.
- HIV therapeutic interventions
- Extraintestinal E. coli infections
- Preventive vaccination studies
Their work encompasses both treatment and prevention strategies for infectious diseases.
Neurological Infections
The investigator conducts research in viral meningitis treatment, with particular focus on HSV-2 related central nervous system infections.
- Antiviral treatments for meningitis
- Clinical outcomes in viral meningitis
- Therapeutic interventions for HSV-2
Their work evaluates treatment efficacy for viral neurological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.